| SteriGenics International, Inc. | |||
| Ticker: | STER | 4020 Clipper Court | |
| Exchange: | NASDAQ-National Market | Fremont, CA 94538 | |
| Industry: | Service (SIC Code 7389) | (510) 770-9000 | |
| Type of Shares: | Common Shares | Filing Date: | 6/25/97 | |
| U.S. Shares: | 2,000,000 | Offer Date: | 8/13/97 | |
| Non-U.S. Shares: | 0 | Filing Range: | $12.00 - $14.00 | |
| Primary Shares: | 2,000,000 | Offer Price: | $12.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.84 | |
| Offering Amount: | $26,000,000 | Selling: | $0.50 | |
| Expenses: | $850,000 | Reallowance: | $0.10 | |
| Shares Out After: | 6,828,769 |
| Manager | Tier | Phone |
| PaineWebber Incorporated | Lead Manager | (212) 713-2626 |
| Piper Jaffray Incorporated | Co-manager | (612) 342-6220 |
| Wheat First Butcher & Singer Capital Markets | Co-manager | (804) 782-3278 |
| Issuer's Law Firm: | Gunderson Dettmer Stough Villeneuve Franklin |
| Bank's Law Firm: | Morrison & Foerster |
| Auditor: | Ernst & Young |
| Registrar/Transfer Agent: | U. S. Stock Transfer Corporation |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 3/31/97 | 3/31/97 | ||||
| Revenue: | $37.67 | Assets: | $91.67 | ||
| Net Income: | $3.21 | Curr Assets: | |||
| EPS: | $0.62 | Liabilities: | $59.19 | ||
| Prior EPS: | Curr Liabilities: | ||||
| Cash Flow/Oper: | $12.18 | Equity: | $32.48 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company is a leading provider of high quality contract sterilization services, with over 18 years of experience in the operation, design and development of Gamma irradiation facilities. The company operates 12 Gamma facilities in six states serving over 850 customers, predominantly in the medical products market. In recent years, the company has expanded into various non-medical sterilization and processing markets. The company's objective is to be the leading provider of high quality contract sterilization services for manufacturers of medical and non-medical products. The market for commercial sterilization is divided between independent suppliers of sterilization and processing services such as the company and certain large manufacturers that have in-house sterilization capabilities. The company estimates that the U.S. market for contract sterilization was approximately $170 million in 1996 and that a similar volume of product was processed by captive sterilizers. There is also a significant market for contract sterilization services outside of the U.S. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund capital expenditures, to redeem the company's outstanding Series A Preferred Stock and for working capital and for general corporate purposes. |